BRYAN M DAVIS
- Type
- Physician · Allopathic & Osteopathic Physicians / Otolaryngology
- Where
- COLORADO SPRINGS, CO
- NPI
- 1336232669
- Received
- $188,608 in 80 records, 2019 to 2025 ($2,146 general, $186,462 research)
- As principal investigator
- $1,429,796 of research payments to others in 123 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 8 | $229 |
| 2025 | Research payment | 2 | $13,980 |
| 2024 | General payment | 17 | $466 |
| 2024 | Research payment | 1 | $12,652 |
| 2023 | General payment | 12 | $283 |
| 2023 | Research payment | 4 | $107,045 |
| 2022 | General payment | 7 | $131 |
| 2022 | Research payment | 2 | $52,784 |
| 2021 | General payment | 12 | $546 |
| 2020 | General payment | 7 | $239 |
| 2019 | General payment | 8 | $248 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Neurent Medical Limited | 9 | $186,462 | 2022–2025 |
| AstraZeneca Pharmaceuticals LP | 30 | $826 | 2020–2025 |
| GlaxoSmithKline, LLC. | 5 | $288 | 2019–2022 |
| Stryker Corporation | 5 | $247 | 2019–2022 |
| AERIN MEDICAL INC. | 5 | $184 | 2019–2023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 | 2021–2024 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 | 2019–2024 |
| Acclarent, Inc | 2 | $68 | 2021–2024 |
| Amgen Inc. | 1 | $63 | 2021 |
| GENZYME CORPORATION | 3 | $54 | 2022–2025 |
| Intersect ENT, Inc. | 2 | $49 | 2019–2020 |
| PFIZER INC. | 2 | $48 | 2024 |
| Optinose US, Inc. | 2 | $31 | 2019–2021 |
| Genentech, Inc. | 1 | $22 | 2019 |
| Lilly USA, LLC | 1 | $19 | 2025 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 | 2022 |
| Integra LifeSciences Corporation | 1 | $17 | 2024 |
| Shire North American Group Inc | 1 | $17 | 2019 |
| SANOFI PASTEUR INC. | 1 | $11 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 9 | $186,462 |
| Food and Beverage | 71 | $2,146 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-22 | Neurent Medical Limited | $2,425 | Research payment | Cash or cash equivalent | NEUROMARK System Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2025 |
| 2025-08-05 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-15 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-09 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-15 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-03 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-01-10 | Neurent Medical Limited | $11,555 | Research payment | Cash or cash equivalent | NEUROMARK System Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2025 |
| 2024-12-18 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-12-04 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-10-29 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-10-24 | PFIZER INC. | $25 | Food and Beverage | In-kind items and services | THROMBIN-JMI Biological, HEMOSTAT | 2024 | |
| 2024-10-07 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | THROMBIN-JMI Biological, HEMOSTAT | 2024 | |
| 2024-10-02 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-09-12 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-09-10 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-06-25 | Integra LifeSciences Corporation | $17 | Food and Beverage | In-kind items and services | ACCLARENT AERA Device, ENT | 2024 | |
| 2024-06-07 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-06-05 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-06-04 | AstraZeneca Pharmaceuticals LP | $0 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-05-22 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-04-11 | Neurent Medical Limited | $12,652 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2024 |
| 2024-03-19 | Takeda Pharmaceuticals U.S.A., Inc. | $27 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2024 | |
| 2024-03-19 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2024 | |
| 2024-02-15 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2024 | |
| 2024-02-08 | Acclarent, Inc | $47 | Food and Beverage | In-kind items and services | RELIEVA SPINPLUS Device, Rhinology | 2024 | |
| 2023-10-31 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-10-24 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-10-11 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-09-07 | AERIN MEDICAL INC. | $16 | Food and Beverage | In-kind items and services | VIVAER STYLUS Device, EAR NOSE & THROAT | 2023 | |
| 2023-08-31 | Neurent Medical Limited | $19,287 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2023 |
| 2023-08-23 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-08-17 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-08-16 | AERIN MEDICAL INC. | $18 | Food and Beverage | In-kind items and services | VIVAER STYLUS Device, EAR NOSE & THROAT | 2023 | |
| 2023-05-31 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-05-02 | Neurent Medical Limited | $42,245 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2023 |
| 2023-04-06 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-03-16 | AERIN MEDICAL INC. | $14 | Food and Beverage | In-kind items and services | VIVAER STYLUS Device, EAR NOSE & THROAT | 2023 | |
| 2023-03-08 | Regeneron Healthcare Solutions, Inc. | $20 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-03-03 | Neurent Medical Limited | $2,425 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Safety and Efficacy Study of the Neurent Medical NEUROMARK System in Subjects With Chronic Rhinitis (MERIDIEN) | 2023 |
| 2023-02-16 | Neurent Medical Limited | $43,088 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Safety and Efficacy Study of the Neurent Medical NEUROMARK System in Subjects With Chronic Rhinitis (MERIDIEN) | 2023 |
| 2023-01-10 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2022-12-12 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-11-30 | Neurent Medical Limited | $3,231 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | 2022 |
| 2022-09-27 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2022 | |
| 2022-09-23 | Neurent Medical Limited | $49,553 | Research payment | Cash or cash equivalent | NEUROMARK Device Device, Electrosurgical, Cutting & Coagulation & Accessories | Safety and Efficacy Study of the Neurent Medical NEUROMARK System in Subjects With Chronic Rhinitis (MERIDIEN) | 2022 |
| 2022-09-20 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AirDuo Digihaler Drug, Respiratory | 2022 | |
| 2022-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | TAKHZYRO Biological, GENETIC DISEASE | 2022 | |
| 2022-07-20 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2022 | |
| 2022-03-16 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-02-07 | Stryker Corporation | $20 | Food and Beverage | In-kind items and services | XPRESS ENT DILATION SYSTEM Device, ENTELLUS | 2022 | |
| 2021-12-09 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-11-30 | Stryker Corporation | $138 | Food and Beverage | In-kind items and services | SCOPIS ENT Device, INSTRUMENTS | 2021 | |
| 2021-10-20 | Stryker Corporation | $30 | Food and Beverage | In-kind items and services | COBRA Device, ARTHROSCOPY | 2021 | |
| 2021-10-19 | AstraZeneca Pharmaceuticals LP | $63 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-19 | Amgen Inc. | $63 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-05 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-30 | GlaxoSmithKline, LLC. | $123 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-09-02 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-08-31 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | TAKHZYRO Biological, GENETIC DISEASE | 2021 | |
| 2021-08-20 | Acclarent, Inc | $21 | Food and Beverage | In-kind items and services | Relieva Spinplus Device, Rhinology | 2021 | |
| 2021-06-23 | Optinose US, Inc. | $13 | Food and Beverage | In-kind items and services | Xhance Drug, Otolaryngology (Ear, Nose, Throat) | 2021 | |
| 2021-03-02 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2021 | |
| 2020-12-04 | Stryker Corporation | $44 | Food and Beverage | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-10-13 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | BREZTRI AEROSPHERE Drug, Respiratory | 2020 | |
| 2020-09-01 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-06-16 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-02-20 | Intersect ENT, Inc. | $24 | Food and Beverage | In-kind items and services | PROPEL Device, Otolaryngology (Ear, Nose, Throat) | 2020 | |
| 2020-02-04 | AERIN MEDICAL INC. | $119 | Food and Beverage | In-kind items and services | VivAer Device, Ear, Nose & Throat | 2020 | |
| 2020-01-28 | SANOFI PASTEUR INC. | $11 | Food and Beverage | In-kind items and services | FLUZONE QUADRIVALENT Biological, Vaccines | 2020 | |
| 2019-12-03 | Stryker Corporation | $13 | Food and Beverage | Cash or cash equivalent | ENTELLUS - XPRESS ENT DILATION SYSTEM Device, ENTELLUS | 2019 | |
| 2019-11-21 | Shire North American Group Inc | $17 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2019 | |
| 2019-10-29 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-08-04 | Genentech, Inc. | $22 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 | |
| 2019-05-21 | Intersect ENT, Inc. | $24 | Food and Beverage | In-kind items and services | PROPEL Device, Otolaryngology (Ear, Nose, Throat) | 2019 | |
| 2019-04-16 | Optinose US, Inc. | $18 | Food and Beverage | In-kind items and services | Xhance Drug, Otolaryngology (Ear, Nose, Throat) | 2019 | |
| 2019-03-14 | GlaxoSmithKline, LLC. | $109 | Food and Beverage | In-kind items and services | NUCALA Biological, RESPIRATORY | 2019 | |
| 2019-03-13 | AERIN MEDICAL INC. | $15 | Food and Beverage | Cash or cash equivalent | Vivaer RF Stylus Device, Ear, Nose & Throat | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-23 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $35,126 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-12-19 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $7,768 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-12-18 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $870 | CTP 1938 BIOKLEAR | 2025 |
| 2025-12-12 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $922 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-12-05 | Paratek Pharmaceuticals, Inc. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $3,902 | A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranas | 2025 |
| 2025-11-25 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $6,584 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-11-25 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $404,159 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-10-22 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $9,427 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2025 |
| 2025-10-17 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $5,578 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-10-17 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $31,542 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-10-16 | Paratek Pharmaceuticals, Inc. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $8,375 | A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranas | 2025 |
| 2025-10-13 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $1,637 | CTP 1938 BIOKLEAR | 2025 |
| 2025-10-02 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $2,375 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-09-09 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $6,365 | CTP 1938 BIOKLEAR | 2025 |
| 2025-09-03 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $5,871 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-13 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $126,171 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-06 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $333 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-06 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $1,167 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-04 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $20,697 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $8,375 | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-07-23 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $9,465 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-06-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $5,677 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-06-10 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $18,071 | CTP 1938 BIOKLEAR | 2025 |
| 2025-06-04 | Eli Lilly and Company | COLORADO OTOLARYNGOLOGY ASSOCIATES DBA COLORADO ENT AND ALLERGY | $14,257 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 3 EFFICACY AND SAFETY STUDY OF LEBRIKI | 2025 |
| 2025-05-21 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $6,553 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-04-23 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $5,879 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-03-31 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $24,910 | CTP 1938 BIOKLEAR | 2025 |
| 2025-03-31 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $657 | CTP 1938 BIOKLEAR | 2025 |
| 2025-02-25 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $5,075 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-02-10 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $22,170 | CTP 1938 BIOKLEAR | 2025 |
| 2025-01-24 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $15,948 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $1,718 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2024 |
| 2024-12-06 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $34,230 | CTP 1938 BIOKLEAR | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $3,124 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $3,124 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $1,799 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $749 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $3,124 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-10-23 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $12,520 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-10-11 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $78 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-10-01 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $4,825 | CTP 1938 BIOKLEAR | 2024 |
| 2024-09-25 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $6,951 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-09-13 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $2,900 | CTP 1125 - SWELL | 2024 |
| 2024-08-27 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $66,994 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-08-16 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $1,500 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-07-24 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $8,514 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-07-12 | Insmed, Inc. | Colorado ENT & Allergy | $1,400 | Insmed BIRCH Study | 2024 |
| 2024-07-12 | Insmed, Inc. | Colorado ENT & Allergy | $2,500 | Insmed BIRCH Study | 2024 |
| 2024-07-12 | Insmed, Inc. | Colorado ENT & Allergy | $1,000 | Insmed BIRCH Study | 2024 |
| 2024-05-10 | GlaxoSmithKline, LLC. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC | $9,461 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-05-01 | Eli Lilly and Company | COLORADO OTOLARYNGOLOGY ASSOCIATES DBA COLORADO ENT AND ALLERGY | $6,800 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 3 EFFICACY AND SAFETY STUDY OF LEBRIKI | 2024 |
| 2024-04-08 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $2,786 | CTP 1125 - SWELL | 2024 |
| 2024-03-13 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $1,857 | CTP 1125 - SWELL | 2024 |
| 2024-01-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $12,078 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2024 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $5,187 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2023 |
| 2023-12-20 | Insmed, Inc. | Colorado ENT & Allergy | $1,500 | Insmed BIRCH Study | 2023 |
| 2023-12-06 | Insmed, Inc. | Colorado ENT & Allergy | $6,000 | Insmed BIRCH Study | 2023 |
| 2023-12-06 | Insmed, Inc. | Colorado ENT & Allergy | $669 | Insmed BIRCH Study | 2023 |
| 2023-07-29 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Colorado Otolaryngology Associates LLC dba Colorado ENT Allergy | $900 | A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATIN | 2023 |
| 2023-03-08 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $4,644 | CTP 1125 - SWELL | 2023 |
| 2023-02-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Colorado Otolaryngology Associates LLC dba Colorado ENT Allergy | $500 | A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATIN | 2023 |
| 2023-01-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $36,452 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2023 |
| 2023-01-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Colorado Otolaryngology Associates LLC dba Colorado ENT Allergy | $350 | A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATIN | 2023 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $1,557 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2022 |
| 2022-12-06 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $2,786 | CTP 1125 - SWELL | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $2,125 | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $5,000 | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $2,875 | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | COLORADO OTOLARYNGOLOGY ASSOCIATES LLC DBA COLORADO ENT & ALLERGY | $500 | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-10 | Optinose US, Inc. | Colorado ENT & Allergy | $1,058 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 |
| 2022-10-10 | Optinose US, Inc. | Colorado ENT & Allergy | $2 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 |
| 2022-09-15 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $1,393 | CTP 1125 - SWELL | 2022 |
| 2022-08-04 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $4,437 | CTP 1125 - SWELL | 2022 |
| 2022-06-25 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $47,104 | CTP 1125 - SWELL | 2022 |
| 2022-03-23 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $10,944 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2022 |
| 2022-03-15 | Intersect ENT, Inc. | Colorado Otolaryngology | $1,400 | EXPAND | 2022 |
| 2022-02-07 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $16,325 | CTP 1125 - SWELL | 2022 |
| 2022-01-12 | Optinose US, Inc. | Colorado ENT & Allergy | $4,130 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $735 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2021 |
| 2021-12-28 | Stryker Corporation | ADVARRA INC | $275 | CLARIFIX RHINITIS RANDOMIZED CONTROLLED TRIAL | 2021 |
| 2021-12-07 | AERIN MEDICAL INC. | COLORADO ENT AND ALLERGY | $2,500 | CTP 1125 - SWELL | 2021 |
| 2021-11-30 | AstraZeneca Pharmaceuticals LP | COLORADO ENT AND ALLERGY | $5,169 | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2021 |
| 2021-11-10 | Intersect ENT, Inc. | COLORADO ENT AND ALLERGY | $1,500 | EXPAND | 2021 |
| 2021-10-13 | Optinose US, Inc. | Colorado ENT & Allergy | $8,946 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2021 |
| 2021-08-19 | Stryker Corporation | ADVARRA INC | $1,050 | CLARIFIX RHINITIS RANDOMIZED CONTROLLED TRIAL | 2021 |
| 2021-08-19 | Stryker Corporation | ADVARRA INC | $1,250 | CLARIFIX RHINITIS RANDOMIZED CONTROLLED TRIAL | 2021 |
| 2021-07-13 | Optinose US, Inc. | Colorado ENT & Allergy | $39,791 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2021 |
| 2021-06-01 | Stryker Corporation | Colorado Otolaryngology | $516 | CLARIFIX RHINITIS RANDOMIZED CONTROLLED TRIAL | 2021 |
| 2021-05-28 | AERIN MEDICAL INC. | CENTRAL COLORADO ENT & ALLERGY | $1,270 | CTP 465 - VIVAER QOL EXTENSION | 2021 |
| 2021-04-15 | Optinose US, Inc. | Colorado ENT & Allergy | $7,894 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2021 |
| 2021-03-12 | Otonomy, Inc. | COLORADO OTOLARYNGOLOGY ASSOCIATES DBA COLORADO ENT AND ALLERGY | $3,547 | A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 G | 2021 |
| 2021-02-25 | AERIN MEDICAL INC. | Colorado ENT & Allergy | $1,500 | CTP1078 - PNN 2-YEAR | 2021 |
| 2021-02-24 | Stryker Corporation | Colorado Otolaryngology | $516 | CLARIFIX RHINITIS RANDOMIZED CONTROLLED TRIAL | 2021 |
| 2021-01-29 | Otonomy, Inc. | COLORADO OTOLARYNGOLOGY ASSOCIATES DBA COLORADO ENT AND ALLERGY | $1,578 | A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 G | 2021 |
| 2021-01-12 | Optinose US, Inc. | Colorado ENT & Allergy | $9,335 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2021 |
| 2021-01-05 | Roche Products Limited | COLORADO OTOLARYNGOLOGY ASSOCIATES PC | $430 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2021 |
| 2020-12-11 | Otonomy, Inc. | Colorado Otolaryngology Associates DBA Colorado ENT & Allergy | $1,463 | A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 G | 2020 |
| 2020-11-13 | Otonomy, Inc. | Colorado Otolaryngology Associates DBA Colorado ENT & Allergy | $6,171 | A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 G | 2020 |
| 2020-11-05 | Otonomy, Inc. | Colorado ENT & Allergy | $6,034 | A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in S | 2020 |
| 2020-10-14 | Optinose US, Inc. | Colorado ENT & Allergy | $12,479 | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Colorado Springs, CO, county El Paso County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Colorado Springs, CO | County El Paso County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 487,887 | 742,999 | 5,862,189 |
| Population, 2020 census P1 | 478,961 | 730,395 | 5,773,714 |
| Median age B01002 | 35.7 | 35.1 | 37.7 |
| Under 18 B01001 | 21.8% | 23.1% | 21.0% |
| 65 and over B01001 | 15.1% | 14.0% | 15.6% |
| Households B11001 | 202,515 | 290,190 | 2,374,218 |
| Foreign born B05002 | 7.6% | 7.2% | 9.8% |
| Median household income B19013 | $84,818 | $90,363 | $95,470 |
| Median family income B19113 | $105,315 | $108,353 | $119,139 |
| Per capita income B19301 | $46,513 | $46,133 | $52,636 |
| Poverty rate B17001 | 9.0% | 8.5% | 9.4% |
| Unemployment rate B23025 | 5.6% | 5.4% | 4.6% |
| Civilian labor force B23025 | 254,603 | 369,615 | 3,235,476 |
| Mean commute (minutes) B08013 | 22.7 | 23.5 | 25.2 |
| Bachelor's degree or higher B15003 | 42.7% | 41.9% | 45.7% |
| Housing units B25001 | 211,353 | 303,482 | 2,589,053 |
| Owner-occupied B25003 | 60.9% | 66.2% | 66.2% |
| Renters B25003 | 39.1% | 33.8% | 33.8% |
| Median home value B25077 | $452,600 | $461,000 | $539,400 |
| Median gross rent B25064 | $1,648 | $1,696 | $1,761 |
| White, not Hispanic B03002 | 65.2% | 65.6% | 64.8% |
| Black B03002 | 5.3% | 5.5% | 3.8% |
| Hispanic or Latino B03002 | 19.3% | 18.7% | 22.5% |
| Asian B03002 | 2.9% | 2.8% | 3.2% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Colorado Springs, CO.
Comments